Horizon CEO: Growth Driver Tepezza ‘Still At A Fraction’ Of Expected Peak Sales

After posting a beat-and-raise Q3, Horizon Therapeutics CEO Tim Walbert discussed the details behind the report with IBD’s Alissa Coram. Thyroid eye disease drug Tepezza delivered triple-digit growth in the quarter, and Walbert says revenue for that and its other key drug Krystexxa are “still at a fraction” of their expected peak sales. Walbert also provided details on Horizon’s drug pipeline, its new manufacturing facility and its CFO’s retirement.

Investor’s Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market research, education and the latest financial and business news to help investors make more money in the stock market.

Learn more. Get more IBD by subscribing to our channel.

Like us on Facebook https://facebook.com/investorsbusinessdaily
Follow us on Twitter https://twitter.com/IBDinvestors
Follow us on Instagram https://www.instagram.com/investorsbusinessdaily
Follow us on StockTwits http://stocktwits.com/InvestorsBusinessDaily